Business Context and Reporting Period
This Form 8-K filing by E. I. du Pont de Nemours and Company (DuPont) covers the period ending August 4, 2017. The report details the final regulatory approvals and the definitive agreement to close the proposed merger of equals with The Dow Chemical Company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and transactional milestones rather than periodic financial performance.
Material Changes
- Regulatory Clearance: On August 2, 2017, DuPont and Dow received the final required regulatory approval and clearance for their merger.
- Closing Date Confirmation: On August 4, 2017, the parties entered into a "Closing Date Agreement" confirming that all conditions to the closing have been satisfied.
- Transaction Timeline: The merger of equals transaction is scheduled to close on August 31, 2017.
- Board Composition: James Gallogly will not serve on the board or advisory committees of the new entity, DowDuPont Inc., due to potential conflicts of interest. Patrick J. Ward is expected to serve on the board.
Guidance, Outlook, and Risks
The filing includes a cautionary statement regarding forward-looking statements, noting that expectations about the consummation of the merger and its anticipated benefits are not guarantees. Risks associated with the transaction are referenced as being fully discussed in the joint proxy statement/prospectus filed on Form S-4 (File No. 333-209869). The company states it assumes no obligation to update these forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the final closing date of August 31, 2017, for the Dow-DuPont merger.
- Confirm the composition of the DowDuPont Inc. board, specifically the exclusion of James Gallogly.
- Review the full text of the Closing Date Agreement (Exhibit 2.1) for specific terms not detailed in this summary.
- Consult the Form S-4 Registration Statement for a comprehensive list of risks associated with the merger.